3 Firms Guide Goldman Sachs On Buying Synthon Stake
The alternative investment arm of Goldman Sachs said Monday that it plans to buy a majority stake in the drugmaker Synthon from British investment firm BC Partners LLP, in a deal...To view the full article, register now.
Already a subscriber? Click here to view full article